What Johnson & Johnson reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 200406 · Filed Oct 26, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 5.6M |
| ±0% |
| $175.2M |
| 23% |
MGTXMeiraGTx Holdings plc | 6.6M | ±0% | $73.1M | 9.6% |
RAPPRapport Therapeutics, Inc. | 1.8M | ±0% | $60M | 7.9% |
CTNMContineum Therapeutics, Inc. | 2M | ±0% | $26.6M | 3.5% |
CBRSCerebras Systems Inc. | 128.6K | +140.1% | $22.9M | 3% |
XNCRXencor Inc | 748.1K | ±0% | $18.7M | 2.5% |
LEGNLegend Biotech Corp | 814.6K | ±0% | $16.2M | 2.1% |
FATEFate Therapeutics Inc | 3.4M | ±0% | $8M | 1.1% |
CVRXCVRx, Inc. | 4M | ±0% | $7M | 0.9% |
PRCTPROCEPT BioRobotics Corp | 357.9K | ±0% | $6.5M | 0.9% |
NMRANeumora Therapeutics, Inc. | 1.8M | ±0% | $1.1M | 0.1% |
VORVor Biopharma Inc. | 53.7K | ±0% | $1M | 0.1% |
LABStandard Biotools Inc. | 312K | ±0% | $231K | 0.1% |
ACETAdicet Bio, Inc. | 22.8K | ±0% | $162.6K | 0.1% |